Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Beijing InnoCare Pharma Tech

33 clinical trials

16 abstracts

Clinical trial
A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors and Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-naïve Patients With MCD Subtype DLBCL
Status: Recruiting, Estimated PCD: 2024-07-30
Clinical trial
A Randomized, Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma
Status: Recruiting, Estimated PCD: 2027-08-25
Clinical trial
A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Status: Recruiting, Estimated PCD: 2024-10-08
Clinical trial
A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 in Patients With Mature B-cell Malignancies
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Not yet recruiting, Estimated PCD: 2030-11-25
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-033 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Status: Completed, Estimated PCD: 2023-12-27
Clinical trial
A Randomized, Controlled, Open, Multicenter Phase 3 Study to Evaluate ICP-022 Versus Chlorambucil Combined With Rituximab for Primary Treatment of Chronic Lymphocytic Leukemia(CLL)/ Small Lymphocytic Lymphoma(SLL)
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase Ib/IIa Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerance, Pharmacokinetics/ Pharmacodynamics(PK/PD) of ICP-022 in Patients With Mild and Moderate Systemic Lupus Erythematosus
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations
Status: Recruiting, Estimated PCD: 2023-11-30
Clinical trial
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity
Status: Active (not recruiting), Estimated PCD: 2026-02-25
Clinical trial
A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia
Status: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase II, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Recurrent/Refractory Central Nervous System Lymphoma and Recurrent/Refractory Secondary Central Nervous System Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis
Status: Recruiting, Estimated PCD: 2023-10-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Moderate-to-severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2023-07-30
Clinical trial
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
An Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects With Varying Degrees of Hepatic Impairment
Status: Recruiting, Estimated PCD: 2023-12-30
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Unveiling the interplay of social factors in cancer survivorship: A comprehensive social determinants of health (SDOH) profile analysis.
Org: Tsinghua University, Beijing InnoCare Pharma Tech, China National Biotec Group, University of Oklahoma Health Sciences Center, Oklahoma City,
Abstract
A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC).
Org: The Fifth Medical Center of PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.
Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.
Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Association of chr11q13 amplification with survival and recurrence in patients with surgically treated hepatocellular carcinoma.
Org: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao Sino-Cell Biomedicine, OrigiMed, Shanghai Henlius Biotech,
Clinical trial
A Multicenter, Open-Label Study to Investigate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Status: Completed, Estimated PCD: 2021-11-05
Clinical trial
A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)
Status: Completed, Estimated PCD: 2024-01-09
Abstract
Analysis of ATM germline mutations in solid tumors from Chinese patients.
Org: China-Japan Friendship Hospital, Beijing InnoCare Pharma Tech, Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Yoko Biomedical,
Abstract
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study.
Org: Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University, Beijing InnoCare Pharma Tech,
Abstract
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
Org: Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Cancer Institute of the State of São Paulo, São Paulo, Brazil, São Paulo, Brazil, Brazil,
Abstract
Determining MSI status by a one-step PCR melting curve analysis of Chinese-specific mononucleotide repeats.
Org: China-Japan Friendship Hospital, Beijing InnoCare Pharma Tech, Department of Translational Medicine Research and New Technologies in Medicine and Surgery, Amoy Diagnostics Co., Ltd., Xiamen Amoytop Biotech,
Abstract
Clinical efficacy and safety of regorafenib for patients with recurrent hepatocellular carcinoma after hepatectomy: A real-world study in China.
Org: Peking University People's Hospital, Beijing InnoCare Pharma Tech,
Abstract
Transarterial chemoembolization combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma: Preoperative or postoperative combination? A prospective clinical study.
Org: Fifth Medical Center of Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group, Aerospace Medical Center, Aerospace Center Hospital,
Abstract
Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.
Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.
Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,